Marijuana withdrawal time – how long does cannabis withdrawal syndrome (DSM-5 CWS) last?

An educational article dedicated to the psychiatric characteristics of marijuana withdrawal syndrome (Cannabis Withdrawal Syndrome, CWS). The content is informational and does not replace medical or psychotherapeutic advice. Cannabis Withdrawal Syndrome is a condition recognized by DSM-5 (codes 292.0 / F12.288). Sudden withdrawal after years of regular use may require psychiatric supervision, especially in individuals with a history of depression. If suicidal thoughts, severe anxiety, or psychotic symptoms occur, immediate consultation with a doctor is necessary. In the case of concurrent pharmacological treatment (antidepressants, gabapentin, NAC), consultation regarding potential interactions is required. Support contacts: Emotional Crisis Helpline for Adults 116 123, Helpline for Children and Youth 116 111, Support Center for People in Mental Health Crisis 800 70 2222.

Withdrawal from marijuana after years of daily use rarely occurs without symptoms. For a long time, the medical community questioned the existence of a withdrawal syndrome from cannabis, considering it a "psychological" suffering. It was only in 2013 that DSM-5 formally introduced the diagnosis of Cannabis Withdrawal Syndrome, based on replicated clinical and neuroimaging studies. In this guide, I present the current state of knowledge: diagnostic criteria, epidemiology, symptom timeline, neurobiological mechanisms, therapeutic methods with documented efficacy, and situations requiring urgent intervention. I rely solely on peer-reviewed literature (JAMA Psychiatry, The Lancet Psychiatry, Drug and Alcohol Dependence, Current Psychiatry Reports) and DSM-5 guidelines.

pillar of the duration of marijuana presence in the body

What is Cannabis Withdrawal Syndrome in light of DSM-5?

Cannabis Withdrawal Syndrome (CWS) is a syndrome of psychophysical symptoms that occur after cessation or significant reduction of intensive and prolonged cannabis use. According to DSM-5 (American Psychiatric Association, 2013), the diagnosis requires the presence of at least 3 out of 7 symptoms within about 7 days after dose reduction. Symptoms must cause clinically significant distress or impairment in functioning.

Seven symptom criteria of DSM-5

The diagnostic list includes: (1) irritability, anger, or aggression, (2) nervousness or anxiety, (3) sleep disturbances (insomnia, disturbing dreams), (4) decreased appetite or weight loss, (5) psychomotor agitation, (6) depressed mood, (7) at least one physical symptom causing significant discomfort (abdominal pain, tremors, sweating, fever, chills, headache). Meeting 3 out of 7 criteria is the diagnostic threshold.

Temporal criteria and frequency of use

DSM-5 specifies that symptoms should occur in a person who has used cannabis "strongly and persistently." In clinical practice, this usually means daily or nearly daily use for at least several months. Symptoms begin within 24-72 hours of the last dose, peak between days 2-6, and resolve within 1-3 weeks (Budney, Current Psychiatry Reports, 2008).

Why was CWS recognized only in 2013?

DSM-IV (1994) did not recognize cannabis withdrawal syndrome as a separate entity. This changed after a series of rigorous experimental studies by Alan Budney and his team (2003-2008), who documented a repeatable pattern of symptoms with predictable dynamics under controlled abstinence. The introduction of CWS into psychiatric classification is not an academic issue. It changes clinical practice: a patient may receive reimbursed therapy, a medical leave, and pharmacological support during withdrawal.

Cannabis Withdrawal Syndrome is an entity introduced into DSM-5 (American Psychiatric Association, 2013) requiring 3 out of 7 symptoms (irritability, anxiety, insomnia, decreased appetite, restlessness, depression, physical discomfort) occurring within a week after stopping cannabis in a person using it intensively and for a long time, with clinically significant distress.

How common is the occurrence of withdrawal syndrome after marijuana?

The National Epidemiologic Survey on Alcohol and Related Conditions III (NESARC-III) study of 36,309 adult Americans found that about 12% of cannabis users in the past year meet the criteria for CWS. Among individuals with cannabis use disorder, this percentage rises to 35-50%, and among patients treated in rehabilitation centers, it reaches 70-95% (Hasin, JAMA Psychiatry, 2016).

Who is most at risk?

The risk of CWS increases with frequency of use, THC dosage, duration of use, and age of onset. Data analysis by Hasin et al. indicates that individuals using daily for over 12 months have about a 5-fold higher risk of full withdrawal syndrome compared to occasional users. Additional risk factors include: co-occurring mental disorders (depression, generalized anxiety), nicotine use, and female gender (stronger anxiety and mood symptoms).

Age and neurodevelopment

Individuals who began regular cannabis use before the age of 18 exhibit withdrawal symptoms that are 30-40% more severe than those who start after the age of 21. The adolescent brain shows greater plasticity of CB1 receptors, which means stronger adaptation and thus a stronger withdrawal effect (Gobbi, The Lancet Psychiatry, 2019).

Differences between THC and medical cannabis

Recreational products with high THC content (above 20%) generate a stronger withdrawal syndrome than medical cannabis with a balanced THC:CBD profile. A study by Freeman et al. (Addiction, 2021) showed that an increase in THC concentration in dried cannabis by every 1% increases the risk of developing cannabis use disorder by 7%. CBD present in balanced preparations may partially suppress the adaptation of CB1 receptors.

According to the NESARC-III analysis conducted by Hasin et al. (JAMA Psychiatry, 2016) on 36,309 respondents, 12% of cannabis users meet the criteria for cannabis withdrawal syndrome, and among individuals with cannabis use disorder, the percentage increases to 35-50%. Daily use lasting over a year increases the risk fivefold.

What is the exact timeline of marijuana withdrawal symptoms?

The temporal dynamics of CWS are repeatable and well documented. According to controlled laboratory studies by Budney et al. (Drug and Alcohol Dependence, 2003, 2004), symptoms appear within 24-72 hours after cessation, peak between the 2nd and 6th day, persist with less intensity for 10-14 days, and subtle sleep and mood issues may persist for 4-12 weeks as Post-Acute Withdrawal Syndrome (PAWS).

Day 1-3: Initiation phase

In the first 24 hours, irritability, anxiety, subtle frustration, and cravings appear. Sleep on the first night often shortens to 4-5 hours, despite subjective fatigue. Anorexia, a feeling of "emptiness in the stomach," and mild headaches occur. Blood pressure and heart rate may increase by 5-10% from baseline. Sweating and slight hand tremors occur in about 30-40% of patients.

Day 2-6: Peak symptoms

Between days 2 and 6, symptoms reach their maximum intensity. Patients report intense irritability, anger outbursts, a "short fuse," but also anxiety and sadness attacks. Insomnia worsens: sleep latency increases, and very vivid, often disturbing dreams occur (REM rebound). This phenomenon results from the sudden removal of REM phase suppression caused by daily THC use. Appetite remains reduced, and weight loss may reach 1-2 kg.

Day 7-14: Gradual subsidence

After the first week, the intensity of symptoms usually decreases by 40-60%. Irritability becomes more situational than constant, craving mainly occurs in triggering contexts. Sleep partially normalizes, although it remains shallower and interrupted. Mood remains labile, with episodes of anhedonia (loss of the ability to feel pleasure). During this period, the risk of relapse is highest.

Week 3-12: PAWS and distant recovery

Post-Acute Withdrawal Syndrome (PAWS) consists of prolonged, milder symptoms persisting for weeks after the acute phase. These include: intermittent sleep, low mood, difficulty concentrating, periodic craving. A study by Bonn-Miller et al. (Journal of Psychiatric Research, 2014) found that 30-45% of individuals with CWS report sleep symptoms even 6 weeks after cessation. Neuroimaging shows normalization of CB1 receptor availability after 4 weeks of abstinence.

Sample timeline table

Symptom	Beginning	Peak	Subsidence	Frequency (% of patients)
Irritability, anger	12-24 h	2-6 day	10-14 days	80-95%
Insomnia, vivid dreams	1-2 day	2-7 day	2-6 weeks	60-75%
Anxiety, fear	24-48 h	3-5 day	1-2 weeks	50-70%
Decreased appetite	1-2 day	3-7 day	1-2 weeks	50-60%
Depressed mood	2-4 day	5-10 day	2-4 weeks	40-60%
Sweating, tremors	24-48 h	2-5 day	7-10 days	30-50%
Headache, abdominal pain	24-72 h	2-4 day	5-10 days	40-55%
Craving	12-24 h	variable	weeks-months	70-90%

Source: compilation based on Budney et al. (2003, 2004, 2008), Bonn-Miller et al. (2014), Hasin et al. (2016).

What neurobiological mechanisms underlie withdrawal?

Marijuana withdrawal syndrome is not a psychological phenomenon but a consequence of measurable changes in the brain. A PET study by Hirvonen et al. (Molecular Psychiatry, 2012) showed that in daily cannabis users, the availability of CB1 receptors in the cortex is reduced by 15-20% compared to non-smokers, and normalization takes about 4 weeks of abstinence. It is this down-regulation of CB1 that explains the central dimension of CWS.

Down-regulation of CB1 receptors

Chronic exposure to THC leads to a decrease in the number and sensitivity of cannabinoid CB1 receptors, especially in the prefrontal cortex, hippocampus, and amygdala. After sudden withdrawal, the endocannabinoid system does not produce enough endogenous cannabinoids (anandamide, 2-AG) to maintain homeostasis. The result is: hyperactivity of glutamatergic neurons, disinhibition of the HPA axis, and anxiety-depressive symptoms.

Hyperactivity of CRH and the stress axis

Studies on animal models (D'Souza et al., Neuropsychopharmacology, 2008) show that THC abstinence activates neurons releasing corticotropin-releasing hormone (CRH) in the bed nucleus of the stria terminalis. CRH is a key mediator of the stress response, and its excess explains the irritability, anxiety, and dysphoria observed in cannabis withdrawal syndrome. The same mechanism is activated during abstinence from alcohol and opioids.

Dopaminergic disorders and anhedonia

Chronic THC increases dopamine release in the nucleus accumbens (reward pathway), while withdrawal leads to hypodopaminergia. The result is anhedonia, lack of motivation, feelings of emptiness, and reduced reactivity to pleasurable stimuli. This is a state in which ordinary activities (eating, sports, social contacts) lose their hedonic value. Withdrawal hypodopaminergia is one of the main risk factors for relapse. Motivational therapies (MET) address this issue, helping the patient consciously build alternative sources of reward.

REM rebound and restoration of sleep architecture

THC strongly suppresses the REM phase of sleep and shortens sleep latency. After withdrawal, REM rebound occurs: a sharp increase in the time and intensity of REM, which explains vivid, often nightmarish dreams. At the same time, deep sleep (N3 phase) remains reduced for several weeks. According to polysomnographic studies by Bolla et al. (Sleep, 2008), full normalization of sleep architecture takes 4-8 weeks after cessation in chronic users.

Hirvonen et al. (Molecular Psychiatry, 2012) showed using PET that in daily cannabis users, the availability of CB1 receptors in the cortex is reduced by 15-20%, and normalization occurs after 4 weeks of abstinence. This down-regulation, along with hyperactivity of the CRH axis, constitutes the biological basis of cannabis withdrawal syndrome.

What does effective treatment of cannabis withdrawal syndrome look like?

Currently, no medication is specifically registered with the FDA or EMA for cannabis withdrawal syndrome. Nevertheless, psychosocial interventions and selected medications have shown effectiveness in controlled studies. According to a review by Brezing and Levin (Drugs, 2018) encompassing 26 RCTs, cognitive-behavioral therapy and motivational enhancement therapy reduce symptoms by 30-50%, and among pharmacotherapy, the best evidence is for N-acetylcysteine (in adolescents) and gabapentin.

Cognitive-behavioral therapy (CBT) and MET

The combination of CBT with motivational enhancement therapy (MET) is currently the standard treatment for cannabis use disorder. A typical protocol includes 9-12 weekly sessions. A meta-analysis by Davis et al. (Journal of Substance Abuse Treatment, 2015) on 23 RCTs showed a moderate effect (Cohen's d = 0.44) in reducing cannabis use and withdrawal symptoms. CBT teaches the identification of triggers, coping strategies for craving, and restructuring thoughts related to use.

Contingency Management

A reinforcement system for documented abstinence (positive urine tests) is one of the most effective behavioral methods. In controlled studies, it increases the percentage of individuals achieving full abstinence 2-3 times compared to CBT alone. However, effectiveness depends on maintaining the incentive: after the program ends, effects gradually diminish.

N-acetylcysteine (NAC) in adolescents

NAC is an amino acid that modulates glutamate balance in the brain. Gray et al. (American Journal of Psychiatry, 2012) demonstrated in an RCT of 116 adolescents that 1200 mg of NAC twice daily for 8 weeks doubled the rate of negative urine tests compared to placebo (OR = 2.4). In adults, the results are more variable. NAC has a good safety profile and is available over the counter, but requires consultation with a doctor before starting.

Gabapentin

Gabapentin (1200 mg/day) in a 12-week RCT by Mason et al. (Neuropsychopharmacology, 2012) reduced withdrawal symptoms, improved executive functions, and increased the rate of abstinence. The mechanism involves modulation of calcium channels and indirect inhibition of glutamate release. The drug requires a prescription and monitoring for drowsiness. It is used off-label and is not registered for this indication.

Pharmaceutical medical marijuana as weaning

Gradual dose reduction using controlled medical cannabis from a pharmacy is a strategy considered for patients with very strong dependence, for whom abrupt withdrawal would worsen functioning. Pilot studies by Trigo et al. (PLOS ONE, 2016) with nabiximols (THC:CBD 1:1 in a spray) suggest effectiveness, but the method requires strict psychiatric supervision and is not recommended as a first-line treatment. In my observation from conversations with patients, weaning using pharmacy medical cannabis acts like a benzodiazepine taper: it reduces the worst symptoms but requires discipline in dosing schedules and a clear plan for ending therapy.

Other interventions: CBD, herbal and adaptogenic

Cannabidiol (CBD), a non-psychoactive cannabinoid, shows preliminary evidence of effectiveness in reducing craving in cannabis users. An RCT by Freeman et al. (The Lancet Psychiatry, 2020) found that 400 mg and 800 mg of CBD daily for 4 weeks reduced cannabis use and withdrawal symptoms compared to placebo. Preparations with lower doses (25-75 mg) did not show effectiveness. Adaptogenic herbs (ashwagandha, rhodiola) may support the regulation of the HPA axis, although they do not replace targeted therapy.

Brezing and Levin (Drugs, 2018) in a review of 26 RCTs indicate that CBT and MET reduce cannabis withdrawal symptoms by 30-50%, NAC 1200 mg twice daily doubles the rate of negative urine tests in adolescents (Gray, AJP 2012), and gabapentin 1200 mg/day reduces withdrawal symptoms and improves executive functions (Mason, Neuropsychopharmacology 2012).

How to take care of sleep and biological rhythm recovery?

Sleep disturbances are the most persistent symptom of CWS and the most common cause of relapse. According to Bonn-Miller et al. (Journal of Psychiatric Research, 2014), 65% of individuals with CWS report insomnia at the peak of symptoms, and 30-45% still have sleep problems after 6 weeks. Sleep hygiene based on CBT-I standards (cognitive-behavioral therapy for insomnia) is a first-line intervention.

CBT-I principles adapted to the abstinence phase

Key recommendations: a consistent wake-up rhythm (even after a sleepless night), limiting time in bed to actual sleep (sleep restriction), getting out of bed after 20 minutes of insomnia and returning only when sleepy, complete exclusion of caffeine after 2 PM, exposure to daylight in the first hour after waking, no screens 60 minutes before sleep. In the first week, sleep may worsen before it improves (restriction effect), which is a normal part of the protocol.

REM rebound and vivid dreams

Intense, often disturbing dreams in the first 2-3 weeks are a physiological consequence of REM rebound. They do not indicate pathology or a relapse of mental illness. It is worth informing the patient about this so they do not interpret nightmares as a 'deterioration'. Vivid dreams usually subside within 3-6 weeks as sleep architecture normalizes (Bolla, Sleep, 2008).

Medications and supplements supporting sleep

Melatonin (0.5-3 mg) 30-60 minutes before sleep can help regulate the circadian rhythm. Magnesium (glycinate, 200-400 mg in the evening) reduces nervous system arousal. Sleep medications from the benzodiazepine or Z-drugs group (zolpidem) may be considered short-term under medical supervision, but carry their own risk of dependence. Trazodone in low doses (25-100 mg) is often used off-label for insomnia after substance withdrawal.

Physical activity and light exposure

Regular aerobic activity (3-5 times a week for 30-45 minutes) improves sleep quality, reduces anxiety, and supports the recovery of the endocannabinoid system. Endogenous anandamide increases during moderate exercise, partially compensating for the deficit in CB1 signaling. Exposure to bright light in the morning (10-30 minutes outside or a 10,000 lux lamp) synchronizes the circadian rhythm.

According to Bonn-Miller et al. (Journal of Psychiatric Research, 2014), insomnia affects 65% of individuals at the peak of CWS and 30-45% after 6 weeks. Polysomnographic studies by Bolla (Sleep, 2008) show REM rebound and reduced deep sleep persisting for 4-8 weeks. CBT-I, melatonin, and physical activity are first-line interventions.

What to avoid during marijuana withdrawal?

Inappropriate strategies can exacerbate CWS symptoms and increase the risk of relapse. According to data from the Substance Abuse and Mental Health Services Administration (SAMHSA, 2019), about 30-50% of individuals attempting abstinence return to use within the first 3 months, and the main risk factors are: solitary withdrawal without support, substitution with other psychoactive substances, and unrealistic expectations regarding the speed of improvement.

Substitution with alcohol or other substances

Replacing marijuana with alcohol, benzodiazepines, or opioids is one of the most common traps. Alcohol worsens REM sleep, exacerbates depression and anxiety, and its use increases the risk of cannabis relapse 2-3 times (Weinberger, Drug and Alcohol Dependence, 2016). Benzodiazepines carry the risk of their own significantly stronger pharmacological dependence. Excessive caffeine (over 400 mg/day) exacerbates anxiety and insomnia.

Silent withdrawal in isolation

Withdrawal without informing loved ones and without professional support decreases the chances of success. According to data from Davis et al. (Journal of Substance Abuse Treatment, 2015), patients participating in structured therapy have 2.5 times higher abstinence rates after 6 months than those attempting on their own. At least one trusted person should know about the process and be able to support during difficult moments.

Sudden withdrawal after years of intensive use without consultation

In patients using daily for over 5 years, especially with a history of depression, anxiety disorders, or psychosis, sudden withdrawal may trigger psychiatric decompensation. Psychiatric consultation is recommended before starting abstinence. Some patients may require short-term pharmacotherapy (SSRIs, gabapentin, mirtazapine) or controlled dose reduction.

Popular 'detoxes' without scientific evidence

Detox drinks, 'cleansing' teas, or supplements promising 'rapid removal of THC' have no documented effectiveness in alleviating withdrawal symptoms. They are often expensive and may interact with actual medications. The only way to 'detoxify' the body from THC is time and abstinence.

Unrealistic expectations

Expecting that after a week 'everything will return to normal' leads to disappointment and relapse. A realistic horizon is 4-8 weeks for significant improvement in mood, sleep, and concentration, and 3-6 months for full normalization of cognitive functioning. Treating the process as a marathon, not a sprint, increases the chances of success.

Weinberger et al. (Drug and Alcohol Dependence, 2016) showed that alcohol use during cannabis withdrawal increases the risk of relapse 2-3 times. Davis et al. (Journal of Substance Abuse Treatment, 2015) documented a 2.5 times higher effectiveness of structured therapy versus self-attempts. Popular detox drinks have no proven effectiveness.

When does marijuana withdrawal require medical help?

Most cases of CWS can be managed on an outpatient basis with psychotherapeutic support. However, according to the guidelines of the American Society of Addiction Medicine (ASAM, 2020), about 10-15% of patients require more intensive intervention due to symptom severity, co-occurring mental disorders, or suicide risk. Awareness of warning signs allows for timely assistance.

Signs requiring immediate consultation

Urgent psychiatric intervention is warranted for: suicidal or self-harming thoughts, psychotic symptoms (hallucinations, delusions), severe insomnia lasting longer than 7 days despite sleep hygiene, extreme agitation or aggression, somatic symptoms such as chest pain or heart rhythm disturbances. Emergency number: 112, emotional crisis helpline: 116 123, Helpline for Children and Youth: 116 111.

Co-occurring mental disorders

Patients with depression, anxiety disorders, PTSD, bipolar disorder, or schizophrenia require coordinated care. Self-medication with cannabis is common in these groups, and withdrawal may reveal or exacerbate the underlying disorder. Treatment should address both the substance use disorder and the primary condition (the 'integrated dual diagnosis care' model).

History of severe dependence and high doses

Daily use of more than 3-5 grams of high THC (20%+) cannabis, long-term exposure, use since adolescence, and co-use of nicotine are signals of increased withdrawal difficulty. For these individuals, treatment in a day or residential center (detox, rehabilitation) may exceed the effectiveness of outpatient treatment.

Where to seek help in Poland?

In Poland, available resources include: State Agency for Solving Alcohol Problems (PARPA, now National Center for Counteracting Addiction), addiction treatment clinics (NFZ), private addiction treatment centers with certification. Crisis Helpline 116 123, National Anti-Drug Helpline 801 199 990, Support Center for People in Mental Health Crisis 800 70 2222. Self-help groups MA (Marijuana Anonymous) operate in larger cities and online.

According to ASAM guidelines (American Society of Addiction Medicine, 2020), 10-15% of patients with CWS require intensive intervention. Signs of urgent consultation: suicidal thoughts, psychotic symptoms, insomnia lasting more than 7 days, extreme aggression. Support numbers in Poland: 116 123 (adults), 116 111 (children and youth), 800 70 2222 (mental crisis).

What products can support the withdrawal process?

No CBD product or adaptogenic herb is a medication and does not replace targeted psychotherapy or pharmacotherapy. However, within the scope of supporting sleep hygiene, reducing anxiety, and regulating the HPA axis, some preparations show preliminary evidence of effectiveness. A study by Freeman et al. (The Lancet Psychiatry, 2020) suggests that CBD at doses of 400-800 mg may reduce withdrawal symptoms, although lower supplemental doses (25-75 mg) have limited evidence.

SOOL Broad Spectrum CBD 5%

CBD oil 5% (500 mg CBD in 10 ml) with a broad spectrum profile, meaning no detectable THC, can be used by individuals wishing to maintain full abstinence from psychoactive substances. Typical supplemental doses (25-50 mg CBD daily, or 10-20 drops) may support relaxation and sleep hygiene. Price: 76 PLN. Product in the store.

SOOL Broad Spectrum CBD 10%

A stronger version of the oil (1000 mg CBD in 10 ml) for those requiring higher doses. However, aiming for doses close to research doses (400 mg/day) would require consultation with a doctor and the use of pharmaceutical preparations. For daily supplementation, 10% allows for easier dosing of 50-100 mg. Price: 99 PLN. Product in the store.

Cannova CBG 15%

Cannabigerol (CBG) oil 15% (1500 mg in 10 ml). CBG has no significant affinity for CB1 receptors, so it does not produce a psychoactive effect. Preliminary studies suggest its potential to modulate the GABAergic axis and improve concentration. Price: 240 PLN. Product in the store.

Mars CBD Hemp Herb 9%

CBD 9% industrial hemp flower (THC below 0.3%, compliant with Polish law). For individuals withdrawing from recreational high-THC marijuana, this product is sometimes used as a 'ritual substitute' without psychoactive effects. Note: individuals aiming for complete abstinence from smoking should consider a non-smoking form. Price: 59 PLN. Product in the store.

Attention: The choice of support form should be consulted with a doctor or addiction therapist, especially when concurrent pharmacological treatment (SSRIs, benzodiazepines, gabapentin) is involved, where interactions may occur. Cannabis products are not medications, and their use does not replace CBT/MET therapy or targeted pharmacotherapy.

Frequently asked questions (FAQ) about marijuana withdrawal syndrome

Is cannabis withdrawal syndrome 'recognized' by medicine?

Yes. CWS is an official diagnostic entity introduced into DSM-5 (2013) and ICD-11 (2022) under codes 292.0 / F12.288 / 6C41.4. It requires 3 out of 7 symptoms (irritability, anxiety, insomnia, decreased appetite, restlessness, depression, physical discomfort) within a week after dose reduction in a person who uses heavily and for a long time (Hasin, JAMA Psychiatry, 2016).

How long does the peak of marijuana withdrawal symptoms last?

The peak occurs between the 2nd and 6th day of abstinence. Acute symptoms (irritability, anxiety, insomnia, decreased appetite) subside within 10-14 days in most patients. Insomnia and vivid dreams may persist for 2-6 weeks. Subtle mood and craving issues (PAWS) may be present for 4-12 weeks (Budney, Drug and Alcohol Dependence, 2003).

Can marijuana withdrawal be dangerous?

Unlike withdrawal from alcohol or benzodiazepines, CWS rarely threatens life. However, in patients with a history of depression, anxiety disorders, or psychosis, psychiatric decompensation and suicidal thoughts may occur. ASAM (2020) recommends psychiatric consultation for daily use over 5 years or co-occurring disorders. In case of crisis: 112, 116 123, 800 70 2222.

Does N-acetylcysteine (NAC) really help quit marijuana?

RCT by Gray et al. (American Journal of Psychiatry, 2012) on 116 adolescents showed that 1200 mg of NAC twice daily for 8 weeks doubled the rate of negative urine tests compared to placebo (OR = 2.4). In adults, the results are more variable and less impressive. NAC is an amino acid with good tolerance, but its use requires medical consultation.

Does CBD help with THC withdrawal?

RCT by Freeman et al. (The Lancet Psychiatry, 2020) found that 400-800 mg of CBD daily for 4 weeks reduced cannabis use and withdrawal symptoms in individuals with cannabis use disorder. Lower supplemental doses (25-75 mg) did not show effectiveness in the same study. CBD is a supportive option and does not replace psychotherapy.

Why do I have nightmares and very vivid dreams after withdrawal?

This is the phenomenon of REM rebound. THC suppresses the REM phase of sleep, and after withdrawal, the body 'makes up' for its deficit by increasing the intensity and amount of REM. According to Boll's research (Sleep, 2008), REM rebound lasts 2-6 weeks after cessation of use. Vivid dreams and nightmares are a normal, transitional consequence of rebuilding sleep architecture.

Will an occasional user experience withdrawal symptoms?

Much less frequently. DSM-5 requires 'heavy and prolonged' use as a condition for diagnosing cannabis withdrawal syndrome. Individuals using 1-2 times a week usually do not develop the full syndrome. According to Hasin (JAMA Psychiatry, 2016), among all cannabis users, 12% meet the criteria for cannabis withdrawal syndrome, but among those using daily for over a year, the percentage rises to 35-50%.

Can pharmaceutical medical marijuana help with gradual withdrawal?

In selected patients with significant dependence, controlled dose reduction using pharmaceutical medical marijuana or nabiximols (Sativex) may reduce the severity of CWS. Trigo et al. (PLOS ONE, 2016) demonstrated the effectiveness of such weaning. The method requires close psychiatric supervision and a clear schedule for ending. It is not a first-line treatment.

Summary: what to remember about marijuana withdrawal time

Cannabis Withdrawal Syndrome is a real, biologically documented phenomenon. The peak of symptoms occurs on the 2nd to 6th day, acute symptoms last 10-14 days, and subtle sleep and mood disturbances may persist for 4-12 weeks. Down-regulation of CB1 receptors and hyperactivity of the CRH axis explain both the emotional and physical components. About 12% of users and 35-50% of individuals with cannabis use disorder meet the criteria for CWS.

The most effective interventions are cognitive-behavioral therapy, MET, contingency management, and among pharmacology: NAC in adolescents, gabapentin in adults. CBD at high doses (400-800 mg) shows preliminary effectiveness. No medication currently has specific registration for CWS. The withdrawal process requires a realistic horizon (4-8 weeks for significant improvement), social support, and professional care in cases of intensified symptoms.

If you are considering quitting marijuana after years of daily use, consult your family doctor, psychiatrist, or addiction therapist. Withdrawal is safer and more effective when planned, supported, and monitored. In a mental crisis: 116 123, 116 111, 800 70 2222.

the article 'How long does marijuana stay in the body'

---

About the author: Michał Waluk, cannabis educator and author of the blog u Bucha. The article is based on peer-reviewed scientific literature (JAMA Psychiatry, The Lancet Psychiatry, Drug and Alcohol Dependence, Current Psychiatry Reports, PMC, American Journal of Psychiatry, Neuropsychopharmacology) and DSM-5 guidelines (APA, 2013), ICD-11 (WHO, 2022), ASAM (2020), and SAMHSA (2019).

Sources:

• American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Cannabis Withdrawal 292.0 / F12.288.
• Hasin DS, Kerridge BT, Saha TD et al. (2016). Prevalence and Correlates of DSM-5 Cannabis Use Disorder, 2012-2013: Findings from the NESARC-III. JAMA Psychiatry, 73(6):588-599.
• Budney AJ, Hughes JR. (2006). The cannabis withdrawal syndrome. Current Opinion in Psychiatry, 19(3):233-238.
• Budney AJ, Hughes JR, Moore BA, Vandrey R. (2004). Review of the validity and significance of cannabis withdrawal syndrome. American Journal of Psychiatry, 161(11):1967-1977.
• Budney AJ, Moore BA, Vandrey RG, Hughes JR. (2003). The time course and significance of cannabis withdrawal. Journal of Abnormal Psychology, 112(3):393-402.
• Budney AJ, Vandrey RG, Stanger C. (2010). Pharmacological and psychosocial interventions for cannabis use disorders. Current Psychiatry Reports.
• Hirvonen J, Goodwin RS, Li CT et al. (2012). Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Molecular Psychiatry, 17(6):642-649.
• Gobbi G, Atkin T, Zytynski T et al. (2019). Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood. The Lancet Psychiatry.
• Freeman TP, Hindocha C, Baio G et al. (2020). Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. The Lancet Psychiatry, 7(10):865-874.
• Brezing CA, Levin FR. (2018). The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal. Drugs, 78(1):93-103.
• Gray KM, Carpenter MJ, Baker NL et al. (2012). A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. American Journal of Psychiatry, 169(8):805-812.
• Mason BJ, Crean R, Goodell V et al. (2012). A proof-of-concept randomized controlled study of gabapentin for cannabis dependence. Neuropsychopharmacology, 37(7):1689-1698.
• Bonn-Miller MO, Boden MT, Bucossi MM, Babson KA. (2014). Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users. Journal of Psychiatric Research.
• Bolla KI, Lesage SR, Gamaldo CE et al. (2008). Sleep disturbance in heavy marijuana users. Sleep, 31(6):901-908.
• Weinberger AH, Platt J, Copeland J, Goodwin RD. (2016). Is cannabis use associated with an increased risk of onset and persistence of alcohol use disorders? Drug and Alcohol Dependence, 161:363-367.
• Davis ML, Powers MB, Handelsman P et al. (2015). Behavioral therapies for treatment-seeking cannabis users: a meta-analysis of randomized controlled trials. Journal of Substance Abuse Treatment.
• Trigo JM, Lagzdins D, Rehm J et al. (2016). Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings. PLOS ONE.
• D'Souza DC, Ranganathan M, Braley G et al. (2008). Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology.
• American Society of Addiction Medicine (ASAM). (2020). The ASAM National Practice Guideline for the Treatment of Opioid and Substance Use Disorder.
• SAMHSA Substance Abuse and Mental Health Services Administration. (2019). Treatment Episode Data Set (TEDS) Annual Report.
• World Health Organization. (2022). International Classification of Diseases, 11th Revision (ICD-11), Disorders Due to Use of Cannabis 6C41.4.